I2O Pharma

Company Overview

Snapshot

Founded in December 2011 by Dan Gelvan, I2O Pharma operates with 1–10 employees. In October 2016, I2O Pharma received funding from Aurum Ventures M.K.I.

Business overview

I2O Pharma specializes in the development of oral versions of injectable drugs, leveraging technology licensed from the Hebrew University of Jerusalem. The company's core technology focuses on drug delivery, aiming to transform how pharmaceuticals are administered. It operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drug Delivery segments, with a focus on the pharmaceuticals market in Israel.

Company Intelligence Q&A

Who founded I2O Pharma?

I2O Pharma was founded by Dan Gelvan.

When was I2O Pharma founded?

I2O Pharma was founded in December 2011.

What is I2O Pharma's primary focus?

I2O Pharma focuses on developing oral versions of injectable drugs using technology licensed from the Hebrew University of Jerusalem.

Which investor participated in I2O Pharma's funding round?

In October 2016, Aurum Ventures M.K.I. participated in a funding round for I2O Pharma.

What is the current product stage of I2O Pharma?

I2O Pharma's product is currently in the clinical trial stage, with plans for human trials.